Clinical Trial SuccessLilly announced positive SURMOUNT-OSA data with the trial hitting significance in both PAP and non-PAP patients, indicating promise for tirzepatide's efficacy in a broad patient population.
Market OpportunityThere are currently no drugs approved to treat OSA, indicating a potential market opportunity for tirzepatide.
Regulatory MilestoneThe company plans to submit regulatory filings for tirzepatide in OSA, which could result in priority review and approval in OSA.